This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sulfametomidine
- DrugBank Accession Number
- DB13485
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Sulfametomidine (DB13485)
- Weight
- Average: 294.33
Monoisotopic: 294.078661501 - Chemical Formula
- C12H14N4O3S
- Synonyms
- Sulfametomidine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Sulfametomidine. Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfametomidine. Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfametomidine. Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfametomidine. Benzylpenicillin Sulfametomidine may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. Bexagliflozin The therapeutic efficacy of Bexagliflozin can be increased when used in combination with Sulfametomidine. Bromocriptine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfametomidine. Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfametomidine. Chloroprocaine The therapeutic efficacy of Sulfametomidine can be decreased when used in combination with Chloroprocaine. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Sulfametomidine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- J01ED03 — Sulfametomidine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Aminobenzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Aniline and substituted anilines / Alkyl aryl ethers / Pyrimidines and pyrimidine derivatives / Organosulfonamides / Imidolactams / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Primary amines show 3 more
- Substituents
- Alkyl aryl ether / Amine / Aminobenzenesulfonamide / Aminosulfonyl compound / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenesulfonyl group / Ether / Heteroaromatic compound show 16 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 940ZL3AHKB
- CAS number
- 3772-76-7
- InChI Key
- QKLSCPPJEVXONT-UHFFFAOYSA-N
- InChI
- InChI=1S/C12H14N4O3S/c1-8-14-11(7-12(15-8)19-2)16-20(17,18)10-5-3-9(13)4-6-10/h3-7H,13H2,1-2H3,(H,14,15,16)
- IUPAC Name
- 4-amino-N-(6-methoxy-2-methylpyrimidin-4-yl)benzene-1-sulfonamide
- SMILES
- COC1=NC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 18460
- ChEBI
- 32163
- ChEMBL
- CHEMBL485940
- ZINC
- ZINC000000002098
- Wikipedia
- Sulfametomidine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.26 mg/mL ALOGPS logP 0.92 ALOGPS logP 1.39 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 7.18 Chemaxon pKa (Strongest Basic) 3.66 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 107.2 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 75.97 m3·mol-1 Chemaxon Polarizability 28.91 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:42 / Updated at February 21, 2021 18:54